Results 111 to 120 of about 20,295 (209)
Endoscopic small bowel therapies for type 2 diabetes
Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1296-1306, October 2026.Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel +4 more
wiley +1 more source
Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review
Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1308-1317, October 2026.Abstract Humans have a primitive defense mechanism called metabolic adaptation that slows voluntary weight loss. It works by downregulating hormones that reduce food intake and by lowering the metabolic rate. Second‐generation GLP‐1 receptor agonists, such as semaglutide or tirzepatide, promote weight loss by targeting this hormonal system to control ...
Ken Fujioka
wiley +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.ABSTRACT Bile acids (BAs) serve not only as emulsifiers for lipid digestion but also as essential signaling molecules, governing various physiological and pathological processes through their interaction with the farnesoid X receptor (FXR) and the takeda G protein‐coupled receptor 5 (TGR5).
Jie Liu +6 more
wiley +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.ABSTRACT Incretin effect helps in regulating glucose homeostasis and maintaining glycaemic control within the human body. This effect is achieved by the two naturally occurring incretin hormones: glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1).
Nora H. J. Alharbi
wiley +1 more source
Regulation of enteroendocrine cell respiration by the microbial metabolite hydrogen sulfide. [PDF]
Front Endocrinol (Lausanne), 2023 Larraufie P +4 more
europepmc +1 more source
Small, Volume 22, Issue 55, 1 October 2026.This study discriminates between sulfated and unsulfated cholecystokinin‐8 gut‐hormone forms at single‐molecule‐level resolution. Using an aerolysin nanopore embedded in a hybrid lipid‐polymer membrane, the system produces distinct electrical signatures enabling highly sensitive detection, even in 20% human serum.
Luca Iesu +3 more
wiley +1 more source
Clinical Obesity, Volume 16, Issue 5, October 2026.ABSTRACT This systematic review and meta‐analysis aimed to compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity. We included randomised controlled trials and observational studies comparing tirzepatide and semaglutide with ≥ 24 weeks of follow‐up.
Giovanna Pagani Paccola +5 more
wiley +1 more source
Enteroendocrine cell types that drive food reward and aversion. [PDF]
Elife, 2022 Bai L +9 more
europepmc +1 more source
Cell Proliferation, Volume 59, Issue 10, October 2026.In cystic fibrosis disorder, CFTR dysfunction drives multilayered intestinal niche disruption, including dysbiosis, inflammation, hypoxia, metabolic stress and genotoxic injury, promoting cell‐state plasticity and a pre‐neoplastic ecosystem. CFTR modulators and environmental factors may partially reshape these processes, highlighting opportunities for ...
Bala Umashankar +5 more
wiley +1 more source